Related references
Note: Only part of the references are listed.Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Craig M. McDonald et al.
LANCET (2017)
Validation of a prognostic score for changes in six-minute walk distance (6MWD) in patients with Duchenne muscular dystrophy (DMD)
N. Goemans et al.
NEUROMUSCULAR DISORDERS (2017)
Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids
Nathalie Goemans et al.
NEUROMUSCULAR DISORDERS (2017)
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy
Eugenio Mercuri et al.
NEUROMUSCULAR DISORDERS (2016)
Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study
Elena S. Mazzone et al.
PLOS ONE (2016)
Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy
Nathalie Goemans et al.
PLOS ONE (2016)
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3: 4 Clinical Trial
Maria V. Irazabal et al.
KIDNEY INTERNATIONAL REPORTS (2016)
Current and emerging treatment strategies for Duchenne muscular dystrophy
Jean K. Mah
NEUROPSYCHIATRIC DISEASE AND TREATMENT (2016)
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study
Thomas Voit et al.
LANCET NEUROLOGY (2014)
ATALUREN TREATMENT OF PATIENTS WITH NONSENSE MUTATION DYSTROPHINOPATHY
Katharine Bushby et al.
MUSCLE & NERVE (2014)
Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy
Anna Mayhew et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2013)
Newborn bloodspot screening for Duchenne Muscular Dystrophy: 21 years experience in Wales (UK)
Stuart J. Moat et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2013)
The cooperative international neuromuscular research group duchenne natural history studya longitudinal investigation in the era of glucocorticoid therapy: Design of protocol and the methods used
Craig M. McDonald et al.
MUSCLE & NERVE (2013)
Evidence-Based Path to Newborn Screening for Duchenne Muscular Dystrophy
Jerry R. Mendell et al.
ANNALS OF NEUROLOGY (2012)
Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy
Anna Mayhew et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2011)
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
Katharine Bushby et al.
LANCET NEUROLOGY (2010)
ASSESSMENT OF REGIONAL BODY COMPOSITION WITH DUAL-ENERGY X-RAY ABSORPTIOMETRY IN DUCHENNE MUSCULAR DYSTROPHY: CORRELATION OF REGIONAL LEAN MASS AND QUANTITATIVE STRENGTH
Andrew J. Skalsky et al.
MUSCLE & NERVE (2009)
Share Paper
